Møller, S. et al. 2012. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncologica. 51, 6 (Jul. 2012), 797–804. DOI:https://doi.org/10.3109/0284186X.2012.681063.